Donor- but not host-derived interleukin-10 contributes to the regulation of experimental graft-versus-host disease
Open Access
- 1 April 2012
- journal article
- host defense-and-pathophysiology
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 91 (4) , 667-675
Abstract
IL-10 is a key immune-regulatory cytokine, and its gene polymorphisms correlate with severity of clinical GVHD. IL-10 is made by a variety of donor and host cells, but the functional relevance of its source and its role in the biology of acute GVHD are not well understood. We used preclinical models to examine the relevance of IL-10−/− in donor and host cellular subsets on the severity of GVHD. IL-10−/− in host tissues or in the donor grafts did not alter donor Teff-mediated severity of GVHD. Furthermore, neither host-derived nor donor Teff-derived IL-10 was required for regulation of GVHD by WT CD4+CD25+ donor Tregs. By contrast, Treg-derived IL-10, although not obligatory, was necessary for optimal reduction of GVHD by mature donor Tregs. Importantly, IL-10 from donor BM grafts was also critical for optimal donor Treg-mediated suppression of GVHD. Together, these data suggest that IL-10 does not contribute to the induction of GVHD severity by the Teffs. However, donor BM graft and Treg-derived IL-10 are important for donor Treg-mediated suppression of GVHD.Keywords
Funding Information
- NIH (AI-075284)
- Scholar in Clinical Research (HL-090775)
- Leukemia Lymphoma Society
- Basic Science Investigator Award
- American Society of Transplantation
This publication has 51 references indexed in Scilit:
- Instability of Foxp3 Expression Limits the Ability of Induced Regulatory T Cells to Mitigate Graft versus Host DiseaseClinical Cancer Research, 2011
- Extracorporeal Photopheresis Attenuates Murine Graft-versus-Host Disease via Bone Marrow–Derived Interleukin-10 and Preserves Responses to Dendritic Cell VaccinationTransplantation and Cellular Therapy, 2011
- Massive ex Vivo Expansion of Human Natural Regulatory T Cells (T regs ) with Minimal Loss of in Vivo Functional ActivityScience Translational Medicine, 2011
- Interleukin-6 Modulates Graft-versus-Host Responses after Experimental Allogeneic Bone Marrow TransplantationClinical Cancer Research, 2011
- Immunization with host-type CD8α+ dendritic cells reduces experimental acute GVHD in an IL-10–dependent mannerBlood, 2010
- Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host diseaseBlood, 2009
- Human T Regulatory Cell Therapy: Take a Billion or So and Call Me in the MorningImmunity, 2009
- Th2 Cell Therapy of Established Acute Graft-Versus-Host Disease Requires IL-4 and IL-10 and Is Abrogated by IL-2 or Host-Type Antigen-Presenting CellsTransplantation and Cellular Therapy, 2008
- Pathophysiology of acute graft-versus-host disease: recent advancesTranslational Research, 2007
- Potential role of interleukin-10-secreting regulatory T cells in allergy and asthmaNature Reviews Immunology, 2005